Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BRAF G469A MDM2 amp TP53 wild-type |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BRAF G469A MDM2 amp TP53 wild-type | lung adenocarcinoma | sensitive | Milademetan + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Mekinist (trametinib) and Milademetan synergistically inhibited proliferation in a lung adenocarcinoma cell line harboring BRAF G469A with wild-type TP53 and MDM2 amplification in culture (PMID: 37182602). | 37182602 |